Xenon Pharmaceuticals (NASDAQ: [[ticker:XENE]]) announced that Ernesto Aycardi will become the company’s chief medical officer. Aycardi, a neurologist, comes to Burnaby, British Columbia-based Xenon from Teva Pharmaceutical (NYSE: [[ticker:TEVA]]), where he was a vice president. His experience also includes positions at EMD Serono, Biogen Idec, and Merck (NYSE: [[ticker:MRK]]). Xenon is developing treatments for neurological disorders.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
